Posted 10/30/2015 9:34 PM (GMT 0)
its anti-MMP9 antibody GS-5745 forward in clinical development for ulcerative colitis and gastric cancer in 2015, per the Abzena website.
http://www.abzena.com/news/172/83/Abzena-provides-an-update-on-progress-with-biopharmaceutical-products-created-using-its-technologies.html